Is antiplatelet therapy safe after intracerebral hemorrhage?

摘要

Although seemingly inappropriate, anti-platelet therapy could benefit patients who have survived intracerebral hemorrhage (ICH) and are therefore at risk of recurrent ICH. The decision to prescribe antiplatelet therapy to a patient after ICH, however, cannot be made without further investigation into the effect of antiplatelet use on recurrent ICH. OBJECTIVES To determine the prevalence of antiplatelet use in ICH survivors and establish whether antiplatelet therapy increases the frequency of recurrent hemorrhage. DESIGN Viswanathan etal. used data from an ongoing prospective cohort study of consecutive patients who had received treatment at the Massachusetts General Hospital following lobar or deep ICH. Exclusion criteria included age less than 55 years, ICH due to a secondary cause and warfarin use.